Skip to main content
Top
Published in: Drugs 2/2000

01-02-2000 | Review Article

Important Drug Interactions in Dermatology

Authors: Thomas Christian Roos, Professor Hans Friedrich Merk

Published in: Drugs | Issue 2/2000

Login to get access

Abstract

Drug interactions can occur at any step from absorption to elimination of a drug, and can induce adverse as well as beneficial effects. Since systemic drugs are increasingly available and important in the treatment of dermatological diseases, a variety of possible interactions between concomitantly administered drugs have to be considered by dermatologists.
The xenobiotic-metabolising enzyme system cytochrome P450 (CYP) is involved in the metabolism of many drugs, regulating their plasma concentrations and activities. Furthermore, the adverse effects of many drugs depend on the basal activity and inducibility of particular CYP isoenzymes in an individual patient. Since drug therapy in dermatological practice is of increasing complexity, and an increasing number of potent systemic drugs have become commonly used therapeutic agents, this review focuses on the following topics with the aim of optimising dermatological drug therapy.
In the first section, all the different types of drug interactions that can occur through pharmacokinetic and pharmacodynamic mechanisms are introduced briefly, and then discussed systematically with special reference to drugs important for dermatologists. Then, the network of drug interactions that may occur from absorption to elimination is presented. The most important drug interactions mediated by CYP isoenzymes are listed. Finally, the importance of pharmacogenetics for the development of new drugs and its potential impact on the optimisation of individual therapy regimens is discussed.
Literature
1.
go back to reference Tatro DS. Drug interactions facts. St Louis: Facts and Comparisons, 1996:7–14 Tatro DS. Drug interactions facts. St Louis: Facts and Comparisons, 1996:7–14
2.
go back to reference Bickers DR. Antifungal therapy: potential interactions with other classes of drugs. J Am Acad Dermatol 1994; 31: S87–90PubMedCrossRef Bickers DR. Antifungal therapy: potential interactions with other classes of drugs. J Am Acad Dermatol 1994; 31: S87–90PubMedCrossRef
3.
go back to reference Stockley IH. Drug interactions. Oxford: Blackwell Science, 1994: 3–6 Stockley IH. Drug interactions. Oxford: Blackwell Science, 1994: 3–6
4.
go back to reference Tucker GT. The rational selection of drug interaction studies: implications of recent advances in drug metabolism. Int J Clin Pharmacol Ther Toxicol 1992; 30: 550–3PubMed Tucker GT. The rational selection of drug interaction studies: implications of recent advances in drug metabolism. Int J Clin Pharmacol Ther Toxicol 1992; 30: 550–3PubMed
5.
go back to reference Van den Bossche H, Koymanns L, Moereels H. P450 inhibitors of use in medical treatment: focus on mechanisms of action. Pharmacol Ther 1995; 67: 79–100CrossRef Van den Bossche H, Koymanns L, Moereels H. P450 inhibitors of use in medical treatment: focus on mechanisms of action. Pharmacol Ther 1995; 67: 79–100CrossRef
6.
go back to reference Roos TC, Jugert FK, Merk HF, et al. Retinoid metabolism in the skin. Pharmacol Rev 1998; 50(2): 315–32PubMed Roos TC, Jugert FK, Merk HF, et al. Retinoid metabolism in the skin. Pharmacol Rev 1998; 50(2): 315–32PubMed
7.
go back to reference Randat JM, Marchbank CR, Dudley MN. Interactions of fluoroquinolones with other drugs: mechanisms, variability, clinical significance, and management. Clin Infect Dis 1992; 14: 272–84CrossRef Randat JM, Marchbank CR, Dudley MN. Interactions of fluoroquinolones with other drugs: mechanisms, variability, clinical significance, and management. Clin Infect Dis 1992; 14: 272–84CrossRef
8.
go back to reference Andersen WK, Feingold DS. Adverse drug interactions clinically important for the dermatologist. Arch Dermatol 1995; 131: 468–73PubMedCrossRef Andersen WK, Feingold DS. Adverse drug interactions clinically important for the dermatologist. Arch Dermatol 1995; 131: 468–73PubMedCrossRef
9.
go back to reference Hochster H, Dieterich D, Bozette S. Toxicity of combined ganciclovir and zidovudine for cytomegalovirus disease associated with AIDS. Ann Intern Med 1990; 113: 111–7PubMed Hochster H, Dieterich D, Bozette S. Toxicity of combined ganciclovir and zidovudine for cytomegalovirus disease associated with AIDS. Ann Intern Med 1990; 113: 111–7PubMed
10.
go back to reference Merk HF, Eichler G. Anaphylaktoide Reaktionen. In: Plewig C, Korting HC, editors. Fortschritte der praktischen dermatologie und Venerologie. Heidelberg: Springer, 1995: 108–15CrossRef Merk HF, Eichler G. Anaphylaktoide Reaktionen. In: Plewig C, Korting HC, editors. Fortschritte der praktischen dermatologie und Venerologie. Heidelberg: Springer, 1995: 108–15CrossRef
11.
go back to reference Sugar EF, Sugar AM, Kreger BE. Effect of common beverages on the dissolution of ketoconazole tablets. AIDS 1995; 6: 1221–2CrossRef Sugar EF, Sugar AM, Kreger BE. Effect of common beverages on the dissolution of ketoconazole tablets. AIDS 1995; 6: 1221–2CrossRef
12.
go back to reference MacKichan JJ. Protein binding drug displacement interactions: fact or fiction. J Clin Pharmacol 1989; 16(2): 65–73CrossRef MacKichan JJ. Protein binding drug displacement interactions: fact or fiction. J Clin Pharmacol 1989; 16(2): 65–73CrossRef
13.
go back to reference Park BK, Pirmohamed M, Kitteringham NR. The role of cytochrome P450 enzymes in hepatic and extrahepatic human drug toxicity. Pharmacol Ther 1995; 68; 385–424PubMedCrossRef Park BK, Pirmohamed M, Kitteringham NR. The role of cytochrome P450 enzymes in hepatic and extrahepatic human drug toxicity. Pharmacol Ther 1995; 68; 385–424PubMedCrossRef
14.
go back to reference Blomley M, Teare EL, deBelder A, et al. Itraconazole and antituberculosis drugs [letter]. Lancet 1990; 336: 1255PubMedCrossRef Blomley M, Teare EL, deBelder A, et al. Itraconazole and antituberculosis drugs [letter]. Lancet 1990; 336: 1255PubMedCrossRef
15.
go back to reference Belpaire FM, Bogaert MG. Cytochrome P450: genetic polymorphism and drug interactions. Acta Clin Belg 1996; 51: 254–60PubMed Belpaire FM, Bogaert MG. Cytochrome P450: genetic polymorphism and drug interactions. Acta Clin Belg 1996; 51: 254–60PubMed
16.
go back to reference Kalow W. Pharmacogenetics: its biologic roots and the medical challenge. Clin Pharmacol Ther 1993; 54: 235–41PubMedCrossRef Kalow W. Pharmacogenetics: its biologic roots and the medical challenge. Clin Pharmacol Ther 1993; 54: 235–41PubMedCrossRef
17.
go back to reference Guengerich FP, Kim DH. In vitro inhibition of dihydropyridine oxidation and aflatoxin B1 activation in human liver microsomes by narangenin and other flavonoids. Carcinogenesis 1990; 11: 2275–9PubMedCrossRef Guengerich FP, Kim DH. In vitro inhibition of dihydropyridine oxidation and aflatoxin B1 activation in human liver microsomes by narangenin and other flavonoids. Carcinogenesis 1990; 11: 2275–9PubMedCrossRef
18.
go back to reference Drayton J, Dickinson G, Rinaldi MG. Coadministration of rifampicin and itraconazole leads to undetectable levels of serum itraconazole [letter]. Clin Infect Dis 1994; 18: 266PubMedCrossRef Drayton J, Dickinson G, Rinaldi MG. Coadministration of rifampicin and itraconazole leads to undetectable levels of serum itraconazole [letter]. Clin Infect Dis 1994; 18: 266PubMedCrossRef
19.
go back to reference Honig P, Baraniuk JN. Adverse effects of H1-receptor antagonists in the cardiovascular system. In: Estelle F, Simons R, editors. Histamine and Hl-receptor antagonists in allergic disease. New York: Marcel Dekker, 1996: 383–412 Honig P, Baraniuk JN. Adverse effects of H1-receptor antagonists in the cardiovascular system. In: Estelle F, Simons R, editors. Histamine and Hl-receptor antagonists in allergic disease. New York: Marcel Dekker, 1996: 383–412
20.
go back to reference Meltzer EO, Welch MJ. Adverse effects of Hl-receptor antagonists in the central nerve system. In: Estelle F, Simons R, editors. Histamine and H1-receptor antagonists in allergic disease. New York: Marcel Dekker, 1996: 357–81 Meltzer EO, Welch MJ. Adverse effects of Hl-receptor antagonists in the central nerve system. In: Estelle F, Simons R, editors. Histamine and H1-receptor antagonists in allergic disease. New York: Marcel Dekker, 1996: 357–81
21.
go back to reference Woosley RL, Chen Y, Freiman P. Mechanism of the cardiotoxic actions of terfenadine. JAMA 1993; 269: 1532–6PubMedCrossRef Woosley RL, Chen Y, Freiman P. Mechanism of the cardiotoxic actions of terfenadine. JAMA 1993; 269: 1532–6PubMedCrossRef
22.
go back to reference Estelle F, Simons R, editors. Histamine and H1-receptor antagonists in allergic disease. New York: Marcel Dekker, 1996 Estelle F, Simons R, editors. Histamine and H1-receptor antagonists in allergic disease. New York: Marcel Dekker, 1996
23.
go back to reference Baciewicz AM, Baciewicz Jr FA. Cyclosporine pharmacokinetic drug interactions. Am J Surg 1989; 157: 264–71PubMedCrossRef Baciewicz AM, Baciewicz Jr FA. Cyclosporine pharmacokinetic drug interactions. Am J Surg 1989; 157: 264–71PubMedCrossRef
24.
go back to reference Periti P, Mazzei T, Mini E. Pharmacokinetic drug interactions of macrolides. Clin Pharmacokinet 1992; 23: 106–31PubMedCrossRef Periti P, Mazzei T, Mini E. Pharmacokinetic drug interactions of macrolides. Clin Pharmacokinet 1992; 23: 106–31PubMedCrossRef
25.
go back to reference Shenfield GM, Griffin JM. Clinical pharmacokinetics of contraceptive steroids. An update. Clin Pharmacokinet 1991; 20: 15–37CrossRef Shenfield GM, Griffin JM. Clinical pharmacokinetics of contraceptive steroids. An update. Clin Pharmacokinet 1991; 20: 15–37CrossRef
26.
go back to reference Okino K, Weibert RT. Warfarin-griseofulvin interaction. Drug Intell Clin Pharm 1986; 20: 291–93PubMed Okino K, Weibert RT. Warfarin-griseofulvin interaction. Drug Intell Clin Pharm 1986; 20: 291–93PubMed
27.
go back to reference Patsalos PN, Duncan JS. Antiepileptic drugs: a review of clinically significant drug interactions. Drug Saf 1993; 125: 269–70 Patsalos PN, Duncan JS. Antiepileptic drugs: a review of clinically significant drug interactions. Drug Saf 1993; 125: 269–70
28.
go back to reference Stafstrom CE, Nohria V, Loganbill H. Erythromycin-induced carbamazepine toxicity: a continuing problem. Arch Pediatr Adolesc Med 1995; 149: 99–101PubMedCrossRef Stafstrom CE, Nohria V, Loganbill H. Erythromycin-induced carbamazepine toxicity: a continuing problem. Arch Pediatr Adolesc Med 1995; 149: 99–101PubMedCrossRef
30.
go back to reference Cameron W, Sun E, Markowith M. Combination use of ritonavir and saquinavir in HIV-infected patients: preliminary safety and activity data [abstract Th.B.934]. In: Program and abstracts of the 11th International Conference on AIDS: 1996 Jul 7–12; Vancouver Cameron W, Sun E, Markowith M. Combination use of ritonavir and saquinavir in HIV-infected patients: preliminary safety and activity data [abstract Th.B.934]. In: Program and abstracts of the 11th International Conference on AIDS: 1996 Jul 7–12; Vancouver
31.
go back to reference Chiba M, Hensleigh M, Lin JH. Hepatic and intestinal metabolism of indinavir, an HIV protease inhibitor, in rat and human microsomes. Biochem Pharmacol 1997; 53: 1187–95PubMedCrossRef Chiba M, Hensleigh M, Lin JH. Hepatic and intestinal metabolism of indinavir, an HIV protease inhibitor, in rat and human microsomes. Biochem Pharmacol 1997; 53: 1187–95PubMedCrossRef
32.
go back to reference Cox SR, Ferry JJ, Batts DH, et al. Delavirdine and marketed protease inhibitors: pharmacokinetic interaction studies in healthy volunteers [abstract A372]. In: Program and Abstracts of the IVth Conference on retroviruses and opportunistic infections: 1997 Jan 22–26; Washington Cox SR, Ferry JJ, Batts DH, et al. Delavirdine and marketed protease inhibitors: pharmacokinetic interaction studies in healthy volunteers [abstract A372]. In: Program and Abstracts of the IVth Conference on retroviruses and opportunistic infections: 1997 Jan 22–26; Washington
33.
go back to reference Havlir D, Cheeseman SH, McLaughlin M, et al. High dose nevirapine: safety, pharmacokinetics and antiviral effect in patients with human immunodeficiency virus infection. J Infect Dis 1995; 171: 537–45PubMedCrossRef Havlir D, Cheeseman SH, McLaughlin M, et al. High dose nevirapine: safety, pharmacokinetics and antiviral effect in patients with human immunodeficiency virus infection. J Infect Dis 1995; 171: 537–45PubMedCrossRef
34.
go back to reference Murpy R, Gagnier P, Lamson M, et al. Effect of nevirapine on pharmacokinetics of indinavir and ritonavir in HIV-patients [abstract A374]. In: Program and Abstracts of the IVth Conference on retroviruses and opportunistic infections: 1997 Jan 22–26; Washington Murpy R, Gagnier P, Lamson M, et al. Effect of nevirapine on pharmacokinetics of indinavir and ritonavir in HIV-patients [abstract A374]. In: Program and Abstracts of the IVth Conference on retroviruses and opportunistic infections: 1997 Jan 22–26; Washington
35.
go back to reference Fiske WD, Mayers D, Wagner K, et al. Pharmacokinetics of DMP266 and indinavir multiple oral doses in HIV-infected individuals. In: Program and Abstracts of the IV Conference on Retroviruses and Opportunistic infections: 1997 Jan 22–26; Washingtonn, A568 Fiske WD, Mayers D, Wagner K, et al. Pharmacokinetics of DMP266 and indinavir multiple oral doses in HIV-infected individuals. In: Program and Abstracts of the IV Conference on Retroviruses and Opportunistic infections: 1997 Jan 22–26; Washingtonn, A568
36.
go back to reference Merk HF, Bickers DR. Dematopharmakologie und Dermato-therapie. Berlin: Blackwell, 1995: 158–61 Merk HF, Bickers DR. Dematopharmakologie und Dermato-therapie. Berlin: Blackwell, 1995: 158–61
37.
go back to reference Larsen FG, Jakobsen P, Knudsen J, et al. Conversion of acitretin to etretinate in psoriatic patients is influenced by ethanol. J Invest Dermatol 1993; 100: 623–7PubMedCrossRef Larsen FG, Jakobsen P, Knudsen J, et al. Conversion of acitretin to etretinate in psoriatic patients is influenced by ethanol. J Invest Dermatol 1993; 100: 623–7PubMedCrossRef
38.
go back to reference Larsen FG, Nielsen-Kudsk F, Jakobsen P, et al. Interaction of etretinate with methotrexate pharmacokinetics in psoriatic patients. J Clin Pharmacol 1990; 30: 802–7PubMed Larsen FG, Nielsen-Kudsk F, Jakobsen P, et al. Interaction of etretinate with methotrexate pharmacokinetics in psoriatic patients. J Clin Pharmacol 1990; 30: 802–7PubMed
39.
go back to reference Antoniskis D, Larsen RA. Acute progressive renal failure with the simultaneous use of amphotericin B and pentamidine. Antimicrob Agents Chemother 1990; 34: 470–2PubMedCrossRef Antoniskis D, Larsen RA. Acute progressive renal failure with the simultaneous use of amphotericin B and pentamidine. Antimicrob Agents Chemother 1990; 34: 470–2PubMedCrossRef
40.
go back to reference Como JA, Dismukes WE. Oral azole drugs as systemic antifungal therapy. N Engl J Med 1994; 330: 263–72PubMedCrossRef Como JA, Dismukes WE. Oral azole drugs as systemic antifungal therapy. N Engl J Med 1994; 330: 263–72PubMedCrossRef
Metadata
Title
Important Drug Interactions in Dermatology
Authors
Thomas Christian Roos
Professor Hans Friedrich Merk
Publication date
01-02-2000
Publisher
Springer International Publishing
Published in
Drugs / Issue 2/2000
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.2165/00003495-200059020-00003

Other articles of this Issue 2/2000

Drugs 2/2000 Go to the issue

Adis Drug Profiles

Dexmedetomidine

Adis New Drug Profile

Lidocaine Patch 5%

Adis New Drug Profile

Insulin Glargine